EntreMed (ENMD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cage Rattler who wrote (1339)	10/28/1998 11:55:00 AM
From: tommysdad	Read Replies (2) of 2135

Ted, I must have found a back-door -- it was free for me. The Yahoo summary seems to be fairly accurate. I am not familiar with this area so cannot comment on the validity of the "post-spinal-cord crush" model. (Squeamish individuals should not read the experimental section). Interesting info from the article -- CM101 is apparently already in the clinic for cancer (reference to effects in cancer patients) and this study used drug that was produced for clinical trials in humans. The researchers are from Vanderbilt University but "have a financial interest" in CarboMed, which funded the work. The way the article reads, the researchers seem to be claiming they developed the hypothesis that anti-angiogenesis agents could be useful in spinal cord injuries. Three notes: (1) PNAS is a prestigious journal but is not peer-reviewed. (2) If CarboMed/Vanderbilt did not patent the concept of treating spinal cord injuries with anti-angiogenesis agents, this could be a new avenue of research for ENMD. Unfortunately they're a little behind. (3) Or maybe I just don't know what I'm talking about.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next